compared to its average ratio and a 36-month beta value of 2.79. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.” The average price point forecasted by analysts for Praxis P
Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Investment analysts at Truist Financial began coverage on shares of Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) in a research report issued on Tuesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $10.00 price target on the stock. A number of other research analysts have also recently commented on PRAX. Jefferies […]
while the 36-month beta value is 2.92.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.” The public float for PRAX is 128.04M, and currently, short sellers hold a 2.12%
Additionally, the 36-month beta value for PRAX is 2.94. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.” The average price predicted by analysts